+23.9%
ONDS vs GSK
+64.9%
-41.0%
-97.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | 0.0% | -2.7% | +2.7% | -0.1% |
| 7D | +8.2% | -4.2% | +12.4% | +8.1% |
| 30D | -16.4% | -7.5% | -8.8% | -16.5% |
| 3M | -26.0% | -3.3% | -22.7% | -26.1% |
| 6M | -22.5% | -9.3% | -13.2% | -22.6% |
| YTD | -21.9% | +1.6% | -23.5% | -22.1% |
| 1Y | +25.7% | +25.5% | +0.3% | +23.0% |
| 3Y | +735.5% | +49.3% | +686.3% | +702.1% |
| 5Y | -0.1% | +46.7% | -46.8% | -4.8% |
| All | +23.9% | +64.9% | -41.0% | +17.5% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling